ADA Scientific Sessions 2025 Abstract

Time in Tight Range with Oral Semaglutide as an Add on to SGLT2i and Metformin Combination in People with Type 2DM—Real-World Evidence from India

By Sonali A. Patange

Trial in peopleInterventions

The paper

Sonali A. Patange

Mumbai

ADA Scientific Sessions 2025 Abstract, 13 Jun 2025

Presented at ADA Scientific Sessions 2025, poster 746-P

doi.org/10.2337/db25-746-p

Nature Medicine4 Oct 2026
Semaglutide may protect kidneys by reducing vascular resistance
Diabetes, Obesity & Metabolism4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
Diabetes & Vascular Disease Research4 Oct 2026
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
The New England Journal of Medicine4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity